Gu X, Luo X, Wang Y, et al
PubMed: 35975308Clinical (RCT / meta-analysis) ref-3.Lizzo G, Migliavacca E, Lamers D, Frezal A, Corthesy J, Vinyes-Pares G, Bosco N, Karagounis LG, Hovelmann U, Heise T, von Eynatten M, Gut P A Randomized Controlled Clinical Trial in Healthy Older Adults to Determine Efficacy of Glycine and N-Acetylcysteine Supplementation on Glutathione Redox Status and Oxidative Damage
Considering only events within various age groups, the ICERs indicated that SGLT2is were not cost-effective for people aged 1039 years or 4059 years for any intervention (although the ICER for SGLT2is in the secondary prevention population was 29,420), while SGLT2is were cost-effective among people aged 6079 years (ICERs of 28,002 and 328 in the primary prevention and secondary prevention populations, respectively) and 80 years, but GLP-1 RAs were not
GHRP-2 availability has decreased due to regulatory concerns, making it harder to find through mainstream providers